A carregar...
Exomics and immunogenics: Bridging mutational load and immune checkpoints efficacy
Anti-PD-1/PD-L1 antibodies are emerging as promising anticancer therapeutics. Interestingly, elevated response rates to these agents are mostly documented among patients with tumors that bear high level of somatic mutations, like melanoma or non-small cell lung carcinoma. We herein formulate the hyp...
Na minha lista:
| Main Authors: | , , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Landes Bioscience
2014
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3937193/ https://ncbi.nlm.nih.gov/pubmed/24605269 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4161/onci.27817 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|